SG Americas Securities LLC Reduces Position in Janux Therapeutics, Inc. $JANX

SG Americas Securities LLC decreased its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 60.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 31,533 shares of the company’s stock after selling 48,284 shares during the period. SG Americas Securities LLC owned about 0.05% of Janux Therapeutics worth $438,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in JANX. AQR Capital Management LLC boosted its position in Janux Therapeutics by 71.7% during the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after buying an additional 4,059 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Janux Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after acquiring an additional 3,393 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Janux Therapeutics by 12.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock valued at $5,033,000 after acquiring an additional 20,657 shares during the period. JPMorgan Chase & Co. increased its position in shares of Janux Therapeutics by 82.9% in the second quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock valued at $5,715,000 after acquiring an additional 112,116 shares during the period. Finally, Legal & General Group Plc raised its stake in shares of Janux Therapeutics by 12.0% during the second quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock valued at $1,094,000 after acquiring an additional 5,055 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JANX shares. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and reduced their price target for the company from $29.00 to $14.00 in a report on Monday, April 20th. JonesTrading lowered their price target on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Truist Financial reiterated a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Finally, UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.15.

Insider Activity

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the sale, the insider owned 75,941 shares in the company, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at $457,265.90. This represents a 5.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Trading Up 3.2%

Shares of Janux Therapeutics stock opened at $16.66 on Thursday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -9.05 and a beta of 2.52. The business has a fifty day simple moving average of $14.41 and a two-hundred day simple moving average of $14.16. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. Analysts predict that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.